Premark Pharma Overview

  • Founded
  • 2018
Founded
  • Status
  • Private
  • Latest Deal Type
  • Seed

Premark Pharma General Information

Description

Developer of novel therapeutic drugs designed for the treatment of ophthalmic diseases. The company's services are engaged in the research and development of PMP2207, an ophthalmic ointment formulation for the potential treatment of blepharitis and other chronic inflammatory eye diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Christoph Merian-Ring 11
  • 4153 Reinach
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Premark Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 07-Mar-2019 Completed Startup
To view Premark Pharma’s complete valuation and funding history, request access »

Premark Pharma Executive Team (1)

Name Title Board Seat Contact Info
Ian Vessey Founder, Board Member & Managing Director
To view Premark Pharma’s complete executive team members history, request access »

Premark Pharma Board Members (5)

Name Representing Role Since
Brian Hilberdink Premark Pharma Board Member 000 0000
Ian Vessey Premark Pharma Founder, Board Member & Managing Director 000 0000
Peter Caldini Self Board Member 000 0000
Trevor Brown Premark Pharma Chairman 000 0000
William Stewart MD Premark Pharma Board Member & Advisor 000 0000
To view Premark Pharma’s complete board members history, request access »